[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"endocarditis-bacterial\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:endocarditis-bacterial":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,45,72,95,117,171],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100053220","phase-3-dalbavancin-therapy-for-infective-endocarditis-100053220",false,"NCT07699211","Dalbavancin Therapy for Infective Endocarditis","Efficacy and Safety of Dalbavancin in the Treatment of Infective Endocarditis Caused by Gram-Positive Cocci","EndoDalba","Inclusion Criteria:\n\n1. ≥ 18 years\n2. written informed consent\n3. Confirmed left-sided infective endocarditis (mitral and\u002For aortic valve) involving native (NV) or prosthetic (PV) valves caused by Gram-positive cocci (staphylococci, streptococci, or enterococci) that are susceptible to dalbavancin.\n\nExclusion Criteria:\n\n1. Hemodynamic instability requiring vasopressor therapy within the last 72 hours prior to randomization\n2. Body temperature ≥38.0°C within the 72 hours prior to randomization\n3. Evidence of pathogen growth in a blood culture within the 72 hours prior to randomization\n4. Presence of a cardiac abscess at the time of randomization\n5. Presence of a remaining infected cardiovascular implantable electronic device (CIED), an infected intravascular graft, or an infected TAVI prosthesis (\"TAVI endocarditis\") at the time of randomization\n6. Duration of effective intravenous antibiotic therapy for endocarditis of \\\u003C 7 days prior to randomization\n7. Remaining duration of required antibiotic therapy for the treatment of endocarditis is less than 10 days (i.e., remaining treatment duration must be at least 10 days)\n8. Hypersensitivity to dalbavancin, vancomycin, teicoplanin, or other components of the investigational drug\n9. Participation in another clinical interventional trial under the German Medicines Act (AMG), Medical Devices Regulation (MDR), or Medical Devices Act (MPDG) without prior consultation and approval by the respective sponsors prior to randomization\n10. Continuous renal replacement therapy (e.g., CVVHD, CVVHDF)\n11. Child B or C liver cirrhosis\n12. Palliative care\n13. Secondary infections requiring a longer course of antibiotic therapy than that intended for the treatment of endocarditis\n14. Oral antibiotic therapy already initiated to treat the current episode of endocarditis\n15. Scheduled cardiac surgery after randomization, within the period designated for antibiotic treatment of endocarditis\n16. Intraspinal or brain abscess (\\> 0.5 cm)\n17. Pregnant and breastfeeding women\n18. Women of childbearing potential, unless the following criteria are met:\n\n    1. Postmenopausal (12 months of natural amenorrhea or 6 months of amenorrhea with serum FSH \\> 40 mIU\u002FmL)\n    2. Postoperative (6 weeks after bilateral oophorectomy with or without hysterectomy)\n    3. Regular and correct use of a contraceptive method with a failure rate \\\u003C 1% per year (considered reliable contraceptive methods include oral hormonal contraception, dermal hormonal contraception, contraceptive patches, long-acting injectable contraceptives, progesterone-releasing implants (Implanon®), intramuscular progesterone, tubal ligation (female sterilization), hormone-releasing intrauterine device (\"hormonal IUD\"), dual barrier methods)\n    4. sexual abstinence\n    5. Vasectomy of the partner","ALL","18 Years",{"count":20,"type":21},184,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This study compares two treatment strategies for antibiotic therapy in endocarditis. The aim of the study is to determine which treatment is more effective overall and better tolerated by patients.\n\nThe first strategy is standard therapy: treatment with proven antibiotics, which are usually administered initially as an intravenous infusion in the hospital and can be switched to oral therapy with tablets later on for suitable patients.\n\nThe second strategy is the study treatment with dalbavancin: This is a long-acting antibiotic. It is administered as a single infusion; for longer treatment durations, a second infusion may be necessary 14 days later.",[27,28],"Endocarditis Infective","Endocarditis, Bacterial",[30,31],"Infective Endocarditis","Dalbavancin","NOT_YET_RECRUITING","2026-07-09",{"date":35,"type":36},"2026-07-13","ACTUAL",{"date":38,"type":21},"2026-12",{"date":40,"type":21},"2029-12",{"name":42,"class":43},"Stefan Hagel","OTHER",9,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":58,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100582983","phase-3-bacteriophages-in-addition-to-antibiotics-for-the-treatment-of-patients-with-infective-endocarditis-100582983","NCT06870409","Bacteriophages in Addition to Antibiotics for the Treatment of Patients With Infective Endocarditis","A Prospective Interventional Randomized Placebo-controlled Multicenter Clinical Trial of the Efficacy, Tolerability and Safety of Phage Therapy in Combination With Standard Antibiotic Therapy in Patients With Infective Endocarditis","PHARAOH","Inclusion Criteria:\n\n* Hospitalisation with active IE or active IE developed in hospital;\n* Definite diagnosis of IE according to modified Duke 2023 criteria or possible diagnosis of IE but managed and treated as IE;\n* Informed consent to participate in the study;\n\nExclusion Criteria:\n\n* Inactive (transferred) IE\n* Non-bacterial thrombotic endocarditis\n* Active oncological diseases\n* Immunosuppressive therapy",{"count":54,"type":21},30,[24],"Infective endocarditis (IE) is an endocardial lesion caused by bacterial and\u002For fungal infection that most commonly affects the heart valves and\u002For the endocardium around implanted intracardiac devices. In general, IE is classified as a rare disease, but there has been a steady increase in incidence, primarily in high-income countries. The danger of IE lies in the high frequency of complicated course of the disease and the risk of lethal outcomes both at the inpatient stage of treatment 25.0% and in the distant period 30-40%. The annual incidence is from 3 to 10 per 100,000 people.\n\nIn addition to the difficulties in the diagnosis of IE, the most challenging aspect is the prescription of effective antibiotic therapy, especially in the context of unidentified etiology of IE and the growth of multi-resistant pathogens. Many solutions are used to achieve successful therapy of IE, including the prescription of combined antibiotic therapy, the use of new modern antibacterial drugs, the prescription of therapy taking into account the sensitivity of the pathogen, but the failure of treatment and the number of resistant pathogens are only increasing. Moreover, antibacterial therapy is relevant both in patients on conservative treatment of IE and after cardiac surgery, among whom the risk of nosocomial or healthcare-associated infections is additionally increased. Thus, new ways of modernising IE therapy are needed. Phage therapy is considered one of the promising strategies \\[6-8\\]. Bacteriophages are certain viruses that naturally infect bacteria and are used as antibacterial treatments. Phagotherapy is used as antibacterial drugs that can induce lysis of target pathogens.",[28],[59,60],"infective endocarditis","bacteriophages","RECRUITING","2026-03-17",{"date":64,"type":36},"2026-03-19",{"date":66,"type":36},"2025-02-05",{"date":68,"type":21},"2029-02-05",{"name":70,"class":43},"University Clinical Hospital na V.V.Vinogradov (branch of RUDN university na Patrice Lumumba)",1,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":71},"100535373","phase-3-new-treatment-of-cardiac-device-infections-immediate-reimplantation-after-removal-of-infected-system-100535373","NCT06250985","New Treatment of Cardiac Device Infections; Immediate Reimplantation After Removal of Infected System","New Treatment of Cardiovascular Implantable Electronic Device (CIED) Infections; Immediate Reimplantation After Removal of Infected System","POET-PPM","Inclusion Criteria:\n\n* Culture positive or negative infection of a CIED acording to PI\n* Indication for removal of device\n* Clinical indication of device removal of existing device (concurrent left-sided IE is not a contraindication).\n* Indication for reimplantation of new device\n* A minimum of 3 days of sufficient antibiotic treatment (intravenous or oral) has been administered and\u002For culture negative antibiotic regimen have been adminstered until blood culture is examined.\n* stabilization criteria fulfilled i.e. I) negativ blood cultures, II) WBC \\\u003C 15 mia\u002FL or reduction of min. 25% and III) CRP \\\u003C50 or min. 25% reduction.\n\nExclusion Criteria:\n\n* Immunoincompetence (active chemotherapy or prednisone treatment \\> 20mg\u002Fday\n* Device-infection within last 6 months (relaps)\n* Septic shock\n* Stabilization criteria not fulfilled after 10 days of suficient antibiotic treatment","110 Years",{"count":82,"type":21},176,[24],"The goal of this randomized clinical trials is to ascertain the safety and efficacy of immediate reimplantation of cardiac electronic implantable devices in patients with endocarditis and device-infections, compared to standard care, i.e. reimplantation at a later procedure date.\n\nThe primary outcome is the occurence of the composite primary endpoint within 6 months of randomization consisting of\n\n* Death\n* Symptomatic embolism (systemic arterial embolism or pulmonary embolism)\n* Bacteremia og pocket-infection\n* Removal of a CIED due to new infection",[28],"2025-10-06",{"date":88,"type":36},"2025-10-08",{"date":90,"type":36},"2024-04-29",{"date":92,"type":21},"2037-12-31",{"name":94,"class":43},"Rigshospitalet, Denmark",{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":17,"minAge":101,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":104,"phases":4,"briefSummary":105,"conditions":106,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":71},"100549437","barts-endocarditis-research-registry-100549437","NCT06434012","Barts Endocarditis Research Registry","Inclusion Criteria:\n\n* • Patients aged 16 and over (Patients under 16 years of age are not admitted to Barts Heart Centre)\n\n  * Patients admitted to Barts Heart Centre with confirmed Endocarditis (see above)\n  * Patients attending outpatients with confirmed\u002Fsuspected Endocarditis\n  * Patients with possible IE who complete treatment for endocarditis\n  * Patients with cardiac device related Endocarditis\n  * Patients with the ability to provide informed consent\n\nExclusion Criteria:\n\n* • Patients with pacemaker pocket infection with no evidence of pacemaker lead or valve infection\n\n  * Patients who refuse consent to be included in the research database\n  * Patients with \"rejected\" endocarditis","16 Years",{"count":103,"type":21},1000,"OBSERVATIONAL","The Barts Endocarditis Research Registry is being set up to give a unique opportunity to assess the characteristics of Infective Endocarditis (IE) in our population cohort, the current use of imaging techniques, as well as the implementation of the ESC guidelines and its consequence in terms of prognosis. All this will help improve the diagnosis and management of IE. The registry will also form the core of all our subsequent work, including interventional studies. The endocarditis research registry is to record the epidemiological, demographic, microbiological, surgical and outcome data in our cohort of endocarditis patients. This work will underpin all future work in endocarditis by clearly defining our patient cohort and the outcomes from treatment. We have a series of studies planned that we believe will influence the management of endocarditis (we are working up proposals for genomic and therapeutic trials that will subsequently be presented for ethical and hospital approval). The registry will be generic to all our planned studies, and will allow us to capture data to assess treatment effectiveness",[30,107,28],"Endocarditis","2025-07-10",{"date":110,"type":36},"2025-07-15",{"date":112,"type":36},"2019-04-24",{"date":114,"type":21},"2029-04-30",{"name":116,"class":43},"Queen Mary University of London",{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":104,"phases":4,"briefSummary":126,"conditions":127,"keywords":143,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":170},"100284234","fosfomycin-iv-for-treatment-of-severely-infected-patients-100284234","NCT02979951","Fosfomycin I.v. for Treatment of Severely Infected Patients","An International, Multicentre, Non-comparative, Non-interventional, Prospective Clinical Registry to Evaluate the Clinical Outcome and Safety of the Treatment of Severely Infected Patients with Fosfomycin I.v.","FORTRESS","Inclusion Criteria:\n\n* Male or female patients aged ≥ 18 years\n* Treatment with fosfomycin according to the (national) Summary of Product Characteristics (SmPC) of fosfomycin i.v.\n* Patients with osteomyelitis, complicated urinary tract infection, nosocomial lower respiratory tract infection, bacterial meningitis\u002Fcentral nervous system infection, bacteraemia\u002Fsepsis, skin and soft tissue infection, endocarditis or other infection, each as far as covered by the respective nationally relevant SmPC\n* Written informed consent of the participant (or person in charge in case of patients incapable of giving consent)\n\nExclusion Criteria:\n\n* Previous documentation of the patient in the present study\n* Patients participating in an interventional clinical trial\n* Patients with known hypersensitivity to fosfomycin or any of the excipients\n* Terminally ill patients\n* Patients with \"do not resuscitate order\"\n* Palliative treatment approach\n* Failure of \\> 3 of the following organ systems: respiratory system, nervous system, cardiovascular system, liver, coagulation, kidney\n* Manifest Human Immunodeficiency Virus (HIV) disease (Acquired Immunodeficiency Syndrome, AIDS)\n* Fosfomycin treatment as 4th line treatment or at later stage\n* Patients with involvement of fungi or mycobacteria in the targeted infection",{"count":103,"type":21},"The purpose of this European, multicentric, prospective, non-interventional study is to document and evaluate the efficacy and safety of the treatment of severely infected patients with intravenously administered fosfomycin, including patients with osteomyelitis, complicated urinary tract infection, nosocomial lower respiratory tract infection, bacterial meningitis\u002Fcentral nervous system infection, bacteraemia\u002Fsepsis, skin and soft tissue infection, endocarditis or other infections, each as far as covered by the respective nationally relevant SmPC.",[128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,28],"Bacterial Infections","Bone Diseases, Infectious","Osteomyelitis","Central Nervous System Bacterial Infections","Meningitis, Bacterial","Encephalitis","Brain Abscess","Urinary Tract Infections","Respiratory Tract Infections","Pneumonia, Bacterial","Skin Diseases, Bacterial","Soft Tissue Infections","Intraabdominal Infections","Sepsis","Bacteremia",[144,145,146,147,148,149,150,151,152,153,128,154,155,129,130,131,132,133,134,135,136,137,138,139,140,141,142,28,156,157,158,159],"Observational Study","Non-Interventional Study","Registries","Prospective","Monitored","Multicentric","International","Fosfomycin","Infectofos","Fomicyt","Gram-Negative Bacterial Infections","Gram-Positive Bacterial Infections","Treatment Outcome","Clinical Efficacy","Microbiological Efficacy","Safety","2024-09-27",{"date":162,"type":36},"2024-10-01",{"date":164,"type":4},"2016-12",{"date":166,"type":21},"2030-12",{"name":168,"class":169},"Infectopharm Arzneimittel GmbH","INDUSTRY",50,{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":177,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":179,"targetDuration":4,"studyType":22,"phases":181,"briefSummary":183,"conditions":184,"keywords":186,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":4},"100486427","effectiveness-of-antibiotic-prophylaxis-of-infective-endocarditis-for-invasive-dental-procedures-in-patients-with-prosthetic-heart-valves-andor-history-of-infective-endocarditis-100486427","NCT05613933","Effectiveness of Antibiotic Prophylaxis of Infective Endocarditis for Invasive Dental Procedures in Patients With Prosthetic Heart Valves and\u002For History of Infective Endocarditis","Effectiveness of Antibiotic Prophylaxis of Infective Endocarditis Before Invasive Dental Procedures in Patients With Prosthetic Heart Valves and\u002For History of Infective Endocarditis: a Prospective, Registry-based, Cluster-randomized Trial in Primary Care","PROPHETS","Inclusion Criteria:\n\n* All French Health Territories (Territoires de santé, TDS) will be included and each TDS will contribute as a cluster for randomization.\n* All dentists working in each TDS will be included.\n* Among individuals receiving an invasive dental procedure, all patients aged 18 years or more identified with prosthetic heart valves or recorded with prior infective endocarditis will be included.\n\nExclusion Criteria:\n\n* No exclusion criteria for health territories, dentists and patient.\n* However, dental procedures that had been performed less than 6 months after the date of first implantation of prosthetic heart valve won't be included.",{"count":180,"type":21},250000,[182],"NA","Infective endocarditis (IE) continues to cause serious morbidity and mortality. To reduce its incidence, antibiotic prophylaxis has been recommended before invasive dental procedures in patients with at risk predispositions. Several studies have examined the effect of antibiotic prophylaxis on the incidence of IE and have brought conflicting results. The investigators aim to evaluate the effectiveness of antibiotic prophylaxis before invasive dental procedures to prevent oral streptococcal infective endocarditis in patients with prosthetic heart valves and\u002For history of IE, using a registry-based, cluster-randomized, controlled trial. In secondary objectives, the investigators aim to analyze changes in dentists' practices.",[28,107,185],"Endocarditis Acute and Subacute",[187,188,189,190,59],"Registry based randomized controlled trial","antibiotic prophylaxy","dentist","invasive dental procedure","2023-01-31",{"date":193,"type":36},"2023-02-02",{"date":195,"type":21},"2023-02-01",{"date":197,"type":21},"2027-12-31",{"name":199,"class":43},"University Hospital, Bordeaux"]